1. Home
  2. Labeler Index
  3. Advanced Rx Pharmacy Of Tennessee, Llc
  4. 80425-0244
  5. NDC Package Code: 80425-0244-1 Lidolog Kit

NDC Package 80425-0244-1 Lidolog Kit

Lidocaine,Kenalog,Povidone Iodine Kit Epidural; Infiltration; Intra-articular; - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
80425-0244-1
Package Description:
1 KIT in 1 CARTON * 25 VIAL in 1 CARTON (70121-1049-5) / 1 mL in 1 VIAL * .9 mL in 1 PACKET (67777-419-02) * 10 VIAL, SINGLE-DOSE in 1 CARTON (55150-164-02) / 2 mL in 1 VIAL, SINGLE-DOSE
Product Code:
80425-0244
Proprietary Name:
Lidolog Kit
Non-Proprietary Name:
Lidocaine, Kenalog, Povidone Iodine
Usage Information:
Lidocaine hydrochloride injection is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of triamcinolone acetonide injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
11-Digit NDC Billing Format:
80425024401
Billing Unit:
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
NDC to RxNorm Crosswalk:
  • RxCUI: 1737757 - lidocaine HCl 2 % in 2 ML Injection
  • RxCUI: 1737757 - 2 ML lidocaine hydrochloride 20 MG/ML Injection
  • RxCUI: 1737757 - lidocaine HCl 2 % per 2 ML Injection
  • RxCUI: 1737757 - lidocaine HCl 40 MG per 2 ML Injection
  • RxCUI: 1792144 - triamcinolone acetonide 40 MG in 1 ML Injection
    • Product Type:
    Human Prescription Drug
    Labeler Name:
    Advanced Rx Pharmacy Of Tennessee, Llc
    Dosage Form:
    Kit - A packaged collection of related material.
    Administration Route(s):
  • Epidural - Administration upon or over the dura mater.
  • Infiltration - Administration that results in substances passing into tissue spaces or into cells.
  • Intra-articular - Administration within a joint.
  • Intramuscular - Administration within a muscle.
  • Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
    • Sample Package:
    No
    Marketing Category:
    UNAPPROVED DRUG OTHER - An unapproved drug product in a marketing category that is not reflected on a particular list.
    Start Marketing Date:
    05-15-2023
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 80425-0244-1?

    The NDC Packaged Code 80425-0244-1 is assigned to a package of 1 kit in 1 carton * 25 vial in 1 carton (70121-1049-5) / 1 ml in 1 vial * .9 ml in 1 packet (67777-419-02) * 10 vial, single-dose in 1 carton (55150-164-02) / 2 ml in 1 vial, single-dose of Lidolog Kit, a human prescription drug labeled by Advanced Rx Pharmacy Of Tennessee, Llc. The product's dosage form is kit and is administered via epidural; infiltration; intra-articular; intramuscular; topical form.

    Is NDC 80425-0244 included in the NDC Directory?

    Yes, Lidolog Kit with product code 80425-0244 is active and included in the NDC Directory. The product was first marketed by Advanced Rx Pharmacy Of Tennessee, Llc on May 15, 2023 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the NDC billing unit for package 80425-0244-1?

    The contents of this package are billed per "each", products billed on a per each basis are usually products dispensed in discreet units.

    What is the 11-digit format for NDC 80425-0244-1?

    The 11-digit format is 80425024401. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-4-1 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-4-180425-0244-15-4-280425-0244-01